Neoadjuvant treatment of Dermatofibrosarcoma Protuberans of pancreas with Imatinib: case report and systematic review of literature

Clinical Sarcoma Research

Jason M Foster¹  William J Hunter²  Peter T Silberstein³  Todd M Stevens⁵  David G Crockett⁴  Mashaal Dhir¹ 

[1] Department of Surgery, Surgical Oncology, 986345 University of Nebraska Medical Center, Omaha, NE 68198-6345, USA;Department of Anatomic Pathology, Creighton University Medical Center, Omaha, NE, USA;Department of Hematology and Oncology, Creighton University Medical Center, Omaha, NE, USA;Department of Hematology and Oncology, University of Nebraska Medical Center, Omaha, NE, USA;Department of Pathology, University of Missouri, Kansas City, MO, USA

关键词: Systematic review;    Imatinib;    DFSP;    Pancreatic metastases;   

Others  :  1092825
DOI  :  10.1186/2045-3329-4-8

 received in 2014-05-14, accepted in 2014-07-07,  发布年份 2014

【 摘 要 】

Dermatofibrosarcoma Protuberans (DFSP) is a rare skin tumor, characterized by frequent local recurrence but is seldom metastatic. It is histologically characterized by storiform arrangement of spindle cells. Cytogenetically, most tumors are characterized by translocation 17:22 leading to overexpression of tyrosine kinase PDGFB which can be targeted with tyrosine kinase inhibitor, Imatinib. We describe the first case of unresectable pancreatic metastases from DFSP treated with neoadjuvant Imatinib and subsequently R0 metastectomy. Additionally, a comprehensive systematic review of DFSP pancreatic metastases and the current published data on the use of Imatinib in DFSP is summarized.

【 授权许可】

   
2014 Dhir et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

【 参考文献 】

• [1]Llombart B, Serra-Guillen C, Monteagudo C, Lopez Guerrero JA, Sanmartin O: Dermatofibrosarcoma protuberans: a comprehensive review and update on diagnosis and management. Semin Diagn Pathol 2013, 30:13-28.
• [2]Criscione VD, Weinstock MA: Descriptive epidemiology of dermatofibrosarcoma protuberans in the United States, 1973 to 2002. J Am Acad Dermatol 2007, 56:968-973.
• [3]McArthur GA: Dermatofibrosarcoma protuberans: a surgical disease with a molecular savior. Curr Opin Oncol 2006, 18:341-346.
• [4]Bowne WB, Antonescu CR, Leung DH, Katz SC, Hawkins WG, Woodruff JM, Brennan MF, Lewis JJ: Dermatofibrosarcoma protuberans: a clinicopathologic analysis of patients treated and followed at a single institution. Cancer 2000, 88:2711-2720.
• [5]Takahira T, Oda Y, Tamiya S, Yamamoto H, Kawaguchi K, Kobayashi C, Oda S, Iwamoto Y, Tsuneyoshi M: Microsatellite instability and p53 mutation associated with tumor progression in dermatofibrosarcoma protuberans. Hum Pathol 2004, 35:240-245.
• [6]Abbott JJ, Oliveira AM, Nascimento AG: The prognostic significance of fibrosarcomatous transformation in dermatofibrosarcoma protuberans. Am J Surg Pathol 2006, 30:436-443.
• [7]Mentzel T, Beham A, Katenkamp D, Dei Tos AP, Fletcher CD: Fibrosarcomatous (“high-grade”) dermatofibrosarcoma protuberans: clinicopathologic and immunohistochemical study of a series of 41 cases with emphasis on prognostic significance. Am J Surg Pathol 1998, 22:576-587.
• [8]Kini H, Raghuveer CV, Pai MR, S K: Fibrosarcomatous Bednar tumor with distant metastases–a case report. Indian J Pathol Microbiol 2004, 47:26-29.
• [9]Westermann GW, Buerger H, Kappes U, Matzkies F, Kisters K: Dermatofibrosarcoma protuberans with lung metastasis in a patient with progressive systemic sclerosis. South Med J 2002, 95:363-365.
• [10]Zorlu F, Yildiz F, Ertoy D, Atahan IL, Erden E: Dermatofibrosarcoma protuberans metastasizing to cavernous sinuses and lungs: a case report. Jpn J Clin Oncol 2001, 31:557-561.
• [11]Minter RM, Reith JD, Hochwald SN: Metastatic potential of dermatofibrosarcoma protuberans with fibrosarcomatous change. J Surg Oncol 2003, 82:201-208.
• [12]Suehara Y, Yazawa Y, Hitachi K: Metastatic Bednar tumor (pigmented dermatofibrosarcoma protuberans) with fibrosarcomatous change: a case report. J Orthop Sci 2004, 9:662-665.
• [13]Yokoyama Y, Murakami Y, Sasaki M, Morifuji M, Hayashidani Y, Kobayashi T, Sudo T, Sueda T: Pancreatic metastasis of dermatofibrosarcoma protuberans. J Gastroenterol 2004, 39:798-800.
• [14]Meguerditchian AN, Wang J, Lema B, Kraybill WG, Zeitouni NC, Kane JM 3rd: Wide excision or Mohs micrographic surgery for the treatment of primary dermatofibrosarcoma protuberans. Am J Clin Oncol 2010, 33:300-303.
• [15]Lemm D, Mugge LO, Mentzel T, Hoffken K: Current treatment options in dermatofibrosarcoma protuberans. J Cancer Res Clin Oncol 2009, 135:653-665.
• [16]Han A, Chen EH, Niedt G, Sherman W, Ratner D: Neoadjuvant imatinib therapy for dermatofibrosarcoma protuberans. Arch Dermatol 2009, 145:792-796.
• [17]Johnson-Jahangir H, Sherman W, Ratner D: Using imatinib as neoadjuvant therapy in dermatofibrosarcoma protuberans: potential pluses and minuses. J Natl Compr Canc Netw 8:881-885.
• [18]Kerob D, Porcher R, Verola O, Dalle S, Maubec E, Aubin F, D’Incan M, Bodokh I, Boulinguez S, Madelaine-Chambrin I, Mathieu-Boue A, Servant JM, de Kerviler E, Janin A, Calvo F, Pedeutour F, Lebbe C: Imatinib mesylate as a preoperative therapy in dermatofibrosarcoma: results of a multicenter phase II study on 25 patients. Clin Cancer Res 2010, 16:3288-3295.
• [19]Lemm D, Muegge LO, Hoeffken K, Aklan T, Mentzel T, Thorwarth M, Schultze-Mosgau S: Remission with Imatinib mesylate treatment in a patient with initially unresectable dermatofibrosarcoma protuberans–a case report. Oral Maxillofac Surg 2008, 12:209-213.
• [20]Savoia P, Ortoncelli M, Quaglino P, Bernengo MG: Imatinib mesylate in the treatment of a large unresectable dermatofibrosarcoma protuberans: a case study. Dermatol Surg 2006, 32:1097-1102.
• [21]Murata H: Fibrosarcomatous variant of dermatofibrosarcoma protuberans with pancreatic metastasis. Int J Dermatol 2014, 53:e140-e142.
• [22]Onoda N: Pigmented dermatofibrosarcoma protuberans (Bednár tumor). An autopsy case with systemic metastasis. Acta Pathol Jpn 1990, 40:935-940.
• [23]Rubin BP, Schuetze SM, Eary JF, Norwood TH, Mirza S, Conrad EU, Bruckner JD: Molecular targeting of platelet-derived growth factor B by imatinib mesylate in a patient with metastatic dermatofibrosarcoma protuberans. J Clin Oncol 2002, 20:3586-3591.
• [24]Baars A, Pinedo HM: Good response to treatment with the selective tyrosine-kinase inhibitor imatinib in a patient with metastatic dermatofibrosarcoma protuberans. Ned Tijdschr Geneeskd 2003, 147:2072-2076.
• [25]Bigby SM, Oei P, Lambie NK, Symmans PJ: Dermatofibrosarcoma protuberans: report of a case with a variant ring chromosome and metastases following pregnancy. J Cutan Pathol 2006, 33:383-388.
• [26]Edelweiss M, Malpica A: Dermatofibrosarcoma protuberans of the vulva: a clinicopathologic and immunohistochemical study of 13 cases. Am J Surg Pathol 2010, 34:393-400.
• [27]Fava P, Stroppiana E, Savoia P, Bernengo MG: Halo nevi related to treatment with imatinib in a dermatofibrosarcoma protuberans patient. J Eur Acad Dermatol Venereol 2010, 24:244-245.
• [28]Gooskens SL, Oranje AP, van Adrichem LN, de Waard-van Der Spek FB, den Hollander JC, van de Ven CP, van den Heuvel-Eibrink MM: Imatinib mesylate for children with dermatofibrosarcoma protuberans (DFSP). Pediatr Blood Cancer 2010, 55:369-373.
• [29]Hong JY, Liu X, Mao M, Li M, Choi DI, Kang SW, Lee J, La Choi Y: Genetic aberrations in imatinib-resistant dermatofibrosarcoma protuberans revealed by whole genome sequencing. PLoS One 2013, 8:e69752.
• [30]Jeon IK, Kim JH, Kim SE, Kim SC, Roh MR: Successful treatment of unresectable dermatofibrosarcoma protuberans on finger with imatinib mesylate and Mohs microsurgery. J Dermatol 2013, 40:288-289.
• [31]Kamar FG, Kairouz VF, Sabri AN: Dermatofibrosarcoma protuberans (DFSP) successfully treated with sorafenib: case report. Clin Sarcoma Res 2013, 3(1):5.
• [32]Kasper B, Lossignol D, Gil T, Flamen P, De Saint Aubain N, Awada A: Imatinib mesylate in a patient with metastatic disease originating from a dermatofibrosarcoma protuberans of the scalp. Anticancer Drugs 2006, 17:1223-1225.
• [33]Kerob D, Pedeutour F, Leboeuf C, Verola O, de Kerviler E, Servant JM, Sarandi F, Bousquet G, Madelaine-Chambrin I, Pruvost C, Calvo F, Janin A, Lebbe C: Value of cytogenetic analysis in the treatment of dermatofibrosarcoma protuberans. J Clin Oncol 2008, 26:1757-1759.
• [34]Kim M, Huh CH, Cho KH, Cho S: A study on the prognostic value of clinical and surgical features of dermatofibrosarcoma protuberans in Korean patients. J Eur Acad Dermatol Venereol 2012, 26:964-971.
• [35]Labropoulos SV, Fletcher JA, Oliveira AM, Papadopoulos S, Razis ED: Sustained complete remission of metastatic dermatofibrosarcoma protuberans with imatinib mesylate. Anticancer Drugs 2005, 16:461-466.
• [36]Llombart B, Sanmartin O, Lopez-Guerrero JA, Monteagudo C, Serra C, Requena C, Poveda A, Vistos JL, Almenar S, Llombart-Bosch A, Guillen C: Dermatofibrosarcoma protuberans: clinical, pathological, and genetic (COL1A1-PDGFB) study with therapeutic implications. Histopathology 2009, 54:860-872.
• [37]Maki RG, Awan RA, Dixon RH, Jhanwar S, Antonescu CR: Differential sensitivity to imatinib of 2 patients with metastatic sarcoma arising from dermatofibrosarcoma protuberans. Int J Cancer 2002, 100:623-626.
• [38]Marakovic J, Vilendecic M, Marinovic T, Lambasa S, Grahovac G: Intracranial recurrence and distant metastasis of scalp dermatofibrosarcoma protuberans. J Neurooncol 2008, 88:305-308.
• [39]Mattox AK, Mehta AI, Grossi PM, Cummings TJ, Adamson DC: Response of malignant scalp dermatofibrosarcoma to presurgical targeted growth factor inhibition. J Neurosurg 2010, 112:965-977.
• [40]McArthur GA, Demetri GD, van Oosterom A, Heinrich MC, Debiec-Rychter M, Corless CL, Nikolova Z, Dimitrijevic S, Fletcher JA: Molecular and clinical analysis of locally advanced dermatofibrosarcoma protuberans treated with imatinib: Imatinib Target Exploration Consortium Study B2225. J Clin Oncol 2005, 23:866-873.
• [41]Mehrany K, Swanson NA, Heinrich MC, Weenig RH, Lee KK, White CR Jr, Devere TS: Dermatofibrosarcoma protuberans: a partial response to imatinib therapy. Dermatol Surg 2006, 32:456-459.
• [42]Mizutani K, Tamada Y, Hara K, Tsuzuki T, Saeki H, Tamaki K, Matsumoto Y: Imatinib mesylate inhibits the growth of metastatic lung lesions in a patient with dermatofibrosarcoma protuberans. Br J Dermatol 2004, 151:235-237.
• [43]Posso-De Los Rios CJ, Lara-Corrales I, Ho N: Dermatofibrosarcoma protuberans in pediatric patients: a report of 17 cases. J Cutan Med Surg 2014, 18:1-6.
• [44]Price VE, Fletcher JA, Zielenska M, Cole W, Viero S, Manson DE, Stuart M, Pappo AS: Imatinib mesylate: an attractive alternative in young children with large, surgically challenging dermatofibrosarcoma protuberans. Pediatr Blood Cancer 2005, 44:511-515.
• [45]Rutkowski P, Debiec-Rychter M, Nowecki Z, Michej W, Symonides M, Ptaszynski K, Ruka W: Treatment of advanced dermatofibrosarcoma protuberans with imatinib mesylate with or without surgical resection. J Eur Acad Dermatol Venereol 2011, 25:264-270.
• [46]Rutkowski P, Van Glabbeke M, Rankin CJ, Ruka W, Rubin BP, Debiec-Rychter M, Lazar A, Gelderblom H, Sciot R, Lopez-Terrada D, Hohenberger P, van Oosterom AT, Schuetze SM, European Organisation for Research and Treatment of Cancer Soft Tissue/Bone Sarcoma Group: Imatinib mesylate in advanced dermatofibrosarcoma protuberans: pooled analysis of two phase II clinical trials. J Clin Oncol 2010, 28:1772-1779.
• [47]Stacchiotti S, Pedeutour F, Negri T, Conca E, Marrari A, Palassini E, Collini P, Keslair F, Morosi C, Gronchi A, Pilotti S, Casali PG: Dermatofibrosarcoma protuberans-derived fibrosarcoma: clinical history, biological profile and sensitivity to imatinib. Int J Cancer 2011, 129:1761-1772.
• [48]Sugiura H, Fujiwara Y, Ando M, Kawai A, Ogose A, Ozaki T, Yokoyama R, Hiruma T, Ishii T, Morioka H, Mugishima H: Multicenter phase II trial assessing effectiveness of imatinib mesylate on relapsed or refractory KIT-positive or PDGFR-positive sarcoma. J Orthop Sci 15:654-660.
• [49]Ugurel S, Mentzel T, Utikal J, Helmbold P, Mohr P, Pfohler C, Schiller M, Hauschild A, Hein R, Kampgen E, Kellner I, Leverkus M, Becker JC, Ströbel P, Schadendorf D: Neoadjuvant imatinib in advanced primary or locally recurrent dermatofibrosarcoma protuberans: a multicenter phase II DeCOG trial with long-term follow-up. Clin Cancer Res 2014, 20:499-510.
• [50]Wang C, Luo Z, Zheng B, Chen Y, Cao X, Wang J, Zhang R, Shi Y: Imatinib mesylate treatment for a Chinese patient with metastatic and recurrent dermatofibrosarcoma protuberans: is sustained partial remission possible? Eur J Cancer Prev 2012, 21:585-587.
• [51]Wicherts DA, van Coevorden F, Klomp HM, van Huizum MA, Kerst JM, Haas RL, van Boven HH, van der Hage JA: Complete resection of recurrent and initially unresectable dermatofibrosarcoma protuberans downsized by Imatinib. World J Surg Oncol 2013, 11:59.
• [52]Wright TI, Petersen JE: Treatment of recurrent dermatofibrosarcoma protuberans with imatinib mesylate, followed by Mohs micrographic surgery. Dermatol Surg 2007, 33:741-744.
• [53]Zhu JH, Li QW, Xiao WH, Sun JZ, Wang RL, Lu JY: Advanced dermatofibrosarcoma protuberans treated with imatinib mesylate. Zhonghua Zhong Liu Za Zhi 2011, 33:470-472.
• [54]Suzuki D, Kobayashi R, Yasuda K, Yamamoto H, Morioka K, Mikawa M, Kobayashi K: Congenital dermatofibrosarcoma protuberans in a newborn infant with a massive back tumor: favorable effects of oral imatinib on the control of residual tumor growth. J Pediatr Hematol Oncol 2011, 33:e304-e306.
• [55]Agbetiafa K: Partial remission of an unresectable dermatofibrosarcoma protuberans in a Togolese patient treated with imatinib. Nouvelles Dermatologiques 2012, 31:167-169.
• [56]Chawla B: Recurrent Bilateral Dermatofibrosarcoma Protuberans of Eyelids. Ophthal Plast Reconstr Surg 2011, 27:e167-e168.
• [57]George S: Dermatofibrosarcoma protuberans case report: when drug therapy can obviate the need for surgery. Community Oncol 2007, 4:462-463.
• [58]Kreze A: Metastasis of Dermatofibrosarcoma from the Abdominal Wall to the Thyroid Gland: case report. Case Rep Med 2012, 118:1-4.
• [59]Vagholkar K, Gopinathan I, Nair S, Nachane S, Joglekar O, Vaishampayan A: Dermatofibrosarcoma protuberans: a deceptive neoplasm. Internet J Oncol 2012., 8(2) http://ispub.com/IJO/8/2/14075 webcite
• [60]Eberst L: Scientific Programme – Proffered Papers (1990). Eur J Cancer 1990, 49:S759-S892.
• [61]Elrafei TNN, Chrysofakis G, Simmons N, Reed LJ: Dermatofibrosarcoma protuberans-derived fibrosarcoma: response to escalated-dose imatinib mesylate (IM) and second-generation kinase inhibitor nilotinib. J Clin Oncol 2011., 29suppl abstr e20529
• [62]Fields RC: Dermatofibrosarcoma protuberans (DFSP): Predictors of Recurrence and the Use of Systemic Therapy. Ann Surg Oncol 2011, 18:328-336.
• [63]Michej W: Treatment of advanced dermatofibrosarcoma protuberans with imatinib mesylate with or without surgical resection. Virchows Arch 2012, 461:S228.
• [64]Neves R: Melanoma 2010 Congress. Pigment Cell Melanoma Res 2010, 23:874-1004.
• [65]Sanmartin O: Locally advanced dermatofibrosarcoma protuberans treated with imatinib followed by Mohs surgery: results of six cases of a single institution. J Am Acad Dermatol 2009, 62:AB107.
• [66]Aguayo Ortiz RA: Dermatofibrosarcoma protuberans facial e imatinib neoadyuvante. Piel 2010, 25:285-287.
• [67]Heinrich MC, Joensuu H, Demetri GD, Corless CL, Apperley J, Fletcher JA, Soulieres D, Dirnhofer S, Harlow A, Town A, McKinley A, Supple SG, Seymour J, Di Scala L, van Oosterom A, Herrmann R, Nikolova Z, McArthur AG, Imatinib Target Exploration Consortium Study B2225: Phase II, open-label study evaluating the activity of imatinib in treating life-threatening malignancies known to be associated with imatinib-sensitive tyrosine kinases. Clin Cancer Res 2008, 14:2717-2725.